<DOC>
	<DOCNO>NCT00246688</DOCNO>
	<brief_summary>The purpose study determine epothilone lead response patient recurrent ovarian cancer progress , last six month since treatment platinum-based chemotherapy . We also aim look safety study drug assess impact infusion duration tolerability .</brief_summary>
	<brief_title>Efficacy Safety Study ZK219477 Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Females age 18 Cancer follow type : epithelial ovarian cancer peritoneal cavity cancer fallopian tube cancer Up 2 previous chemotherapy ; recent must platinum contain therapy Progression disease symptomatic relapse , within 6 month previous therapy 4 week since prior radiotherapy chemotherapy 3 week since prior immunotherapy Adequate recovery previous surgery , radiotherapy , chemotherapy ( exclude alopecia ) Survival expectation 3 month Exclusion Criteria : More 2 previous chemotherapy Previous treatment epothilones Use investigational drug within 4 week start study treatment inadequate recovery toxic effect therapy Previous radiation whole pelvis Symptomatic brain metastasis require wholebrain irradiation Active infection Any malignancy except : Nonmelanoma skin cancer Carcinoma situ cervix Malignancy treatment 5 year ago without relapse Mixed mesodermal tumor Prior hormone therapy malignancy previous month Women childbearing potential</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>